| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2023-036 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2023 年 09 月 27 日(星期三)上午 09:00-10:00 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 三、 参加人员 董事长兼总经理：徐久振先生 董事会秘书：赵新安先生 重要内容提示： 投资者可于 2023 年 09 月 20 日(星期三)至 09 月 2 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[12]. - The company's operating revenue for the first half of the year was ¥185,450,923.40, representing a year-on-year increase of 4.57%[19]. - Net profit attributable to shareholders decreased by 38.49% to ¥30,914,243.64 compared to the same period last year[19]. - The basic earnings per share dropped by 36.00% to ¥0.16, while the diluted earnings per share also fell by 36.00% to ¥0.16[19]. - The net cash flow from operating activities was negative at -¥22,046,991.59, representing a 44.54% increase in cash outflow compared to the same period last year[19]. - The actual revenue growth rate for the first half of 2023, excluding specific products, was 21.22%[20]. - The company reported a net profit attributable to shareholders of 34,534,185.30 CNY, excluding the impact of share-based payment expenses of 3,619,941.66 CNY[54]. - The company achieved operating revenue of ¥185,450,923.40, an increase of 4.57% year-on-year[74]. - Net profit for the period was ¥30,914,243.64, a decrease of 38.49% compared to the previous year[74]. Research and Development - Research and development expenses increased by 40% to RMB 80 million, reflecting the company's commitment to innovation and new technology[12]. - Research and development expenses accounted for 14.21% of operating revenue, an increase of 4.74 percentage points from the previous year[19]. - The company achieved a total R&D investment of ¥26,355,711.27, representing a 56.86% increase compared to ¥16,802,484.58 in the same period last year[40]. - The number of R&D personnel increased to 179, accounting for 30.29% of the total workforce, up from 26.36% in the previous year[45]. - The company has developed over 3,200 analytical methods, enhancing its quality control capabilities[47]. - The company obtained 6 new patents during the reporting period, including 3 invention patents and 3 utility model patents, bringing the total number of invention patents to 20 and utility model patents to 49[37]. Market Expansion and Product Development - User data showed a 30% increase in active users, bringing the total to 1.5 million users by the end of June 2023[12]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2024[12]. - New product launches are expected to contribute an additional RMB 100 million in revenue by the end of 2023, focusing on innovative biochemical solutions[12]. - The company has developed a diverse range of products across four major fields: high-end chemistry, life sciences, analytical chromatography, and materials science, under the "Aladdin" brand[33]. - The company is focused on developing its own "Aladdin" brand research reagents and "Chip Silicon Valley" brand experimental consumables, moving away from foreign brand agency strategies[64]. Operational Efficiency and Cost Management - The gross profit margin improved to 60%, up from 55% in the previous year, indicating better cost management and pricing strategies[12]. - The company has implemented new strategies to enhance operational efficiency, aiming for a 10% reduction in operational costs by the end of 2023[12]. - The company is actively expanding its product offerings to meet the diverse needs of downstream research institutions, which may lead to increased inventory risks if market demands are not accurately anticipated[66]. Environmental and Regulatory Compliance - The company has established an environmental protection mechanism to manage its environmental impact[101]. - The company reported stable emissions of pollutants, with chemical oxygen demand at 19 mg/L, total nitrogen at 0.95 mg/L, and total phosphorus at 0.12 mg/L, all within the regulatory limits[103]. - The company successfully managed hazardous waste disposal through qualified third-party services, ensuring compliance with environmental regulations[105]. - No administrative penalties were imposed on the company during the reporting period for environmental issues, indicating compliance with regulations[109]. Shareholder and Governance Commitments - The company has committed to a share lock-up period of 36 months from the date of the stock market listing for major shareholders and related parties[113]. - Major shareholders and executives have a long-term share lock-up commitment, ensuring stability in ownership[114]. - The company has a commitment to resolve related party transactions, which is crucial for maintaining transparency and trust with investors[115]. - The company has outlined a plan to ensure compliance with commitments made during the refinancing process, which is vital for financial integrity[115]. Financial Management and Investment - The total investment amount for the reporting period reached ¥7,007,986, representing a 100% increase compared to the previous year[86]. - The company has engaged in cash management with idle funds, investing in various bank products with interest rates ranging from 2.00% to 2.10%[168]. - The total amount raised from the convertible bond issuance was approximately CNY 387.40 million, with a net amount of CNY 373.38 million after deducting issuance costs[164]. - The company plans to invest 104,000,000.00 in the construction of a high-purity reagent research and development center, with a projected completion date in March 2024[165]. Risks and Challenges - The company faces risks related to low market share in the domestic research reagent market, which is primarily dominated by foreign enterprises[61]. - The company is facing potential risks from core technology leakage, as key proprietary technologies are primarily held by a small number of core technical personnel[57]. - The company’s comprehensive gross margin and net margin are currently high, but there is a risk of margin decline due to increased competition or rising raw material costs[65]. - The company's inventory at the end of the reporting period was valued at 440,233,314.42 CNY, accounting for 29.59% of total assets, which poses a risk to operational cash flow[66].

西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2023 年半年度持续督导跟踪报告 保荐人（主承销商） （陕西省西安市新城区东新街 319 号 8 幢 10000 室） 西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 | 序号 | 工作内容 | 持续督导工作情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对具 | 已建立健全并有效执行持续 | | | | 督导工作制度，已根据公司的 | | | 体的持续督导工作制定相应的工作计划。 | 具体情况制定了相应的工作 | | | | 计划。 | | | 根据中国证监会相关规定，在持续督导工作开始前， | 保荐人已与公司签订持续督 | | 2 | 与上市公司或相关当事人签署持续督导协议，明确 | 导协议，该协议已明确了双方 | | | 双方在持续督导期间的权利义务。 | 在持续督导期间的权利义务。 | | | | 年上半年，保荐人通过 2023 | | | 通过日常沟通、定期回访、现场检查、尽职调查等 | 日常沟通、定期或不定期回 | | 3 | 方式开展持续督导工作。 | 访、现场检查等方式， ...

上海阿拉丁生化科技股份有限公司 独立董事关于第四届董事会第十二次会议相关事项的独立意见 独立董事签字: 黄遵顺 签署日期: w (本页无正文,为《上海阿拉丁生化科技股份有限公司独立董事关于第四届董事 会第十二次会议相关事项的独立意见》签字页） 2、公司审议程序符合相关法律法规和《公司章程》的规定，不存在损害公 司及其他股东，特别是中小股东利益的情形，符合全体股东的利益。 3、同意本议案。 （以下无正文） （本页无正文，为《上海阿拉丁生化科技股份有限公司独立董事关于第四届董事 会第十二次会议相关事项的独立意见》签字页) /V: 独立董事签字: 孙 佳 上海阿拉丁生化科技股份有限公司（以下简称"公司"）第四届董事会第十二 次会议于2023年8月28日以现场结合通讯方式召开，根据《中华人民共和国公司 法》（以下简称"《公司法》"）、《上海证券交易所科创板股票上市规则》（以下简 称"《上市规则》"）、《上海阿拉丁生化科技股份有限公司章程》（以下简称"《公 司章程》"）、《上海阿拉丁生化科技股份有限公司独立董事工作制度》等法律、 法规及规章制度的有关规定，作为公司的独立董事，我们现对公司第四届董事会 第十二次会议审议的 ...

| | | 上海阿拉丁生化科技股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》、《上海证券交易所科创板股票上市规则》和《上海证券交易所科创板上市公 司自律监管指引第 1 号——规范运作》及《上海阿拉丁生化科技股份有限公司募 集资金管理制度》（以下简称"《募集资金管理制度》"）等规定，上海阿拉丁生化 科技股份有限公司（以下简称"公司"）董事会编制了截至 2023 年 6 月 30 日的募 集资金存放与实际使用情况的专项报告，具体如下： 一、 募集资金基本情况 1、首次公开发行股票 经上海证券交易所科创板上市委员会 2020 年 8 月 11 日审核同意，并经中国 证券监督管理委员会 2020 年 9 月 7 日《关于同意上海阿拉丁生化科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕2116 号）注册同意，公司 向社会公开发行人民币普通股（A 股）股票 ...

西部证券股份有限公司 关于上海阿拉丁生化科技股份有限公司 2022年度持续督导工作现场检查报告 上海证券交易所： （四）现场检查人员：滕晶、贾喻杰 （五）现场检查内容：公司治理及内部控制，信息披露情况，公司独立性以及 与控股股东、实际控制人及其他关联方资金往来情况，募集资金使用情况、关联交 易、对外担保、重大对外投资情况，公司经营状况等。 （六）现场检查手段：与公司相关董事、高级管理人员进行访谈；查看上市公 司主要经营、管理场所；查阅并收集公司持续督导期间召开的历次三会文件；查阅 并收集上市公司募集资金台账、募集资金使用凭证、募集资金专户银行对账单等资 料；查阅并收集公司建立或更新的有关内控制度文件；查阅上市公司定期报告、临 时报告等信息披露文件；核查公司对外投资的相关资料；检查公司及董监高所做承 诺及履行情况。 二、现场检查的具体事项及意见 1 （一）公司治理和内部控制情况 根据《上海证券交易所上市公司自律监管指引第11号——持续督导》等有关法 律、法规的规定，西部证券股份有限公司（以下简称"保荐人"）作为上海阿拉丁 生化科技股份有限公司（以下简称"阿拉丁"、"公司"）持续督导阶段的保荐人， 于2023年7 ...

重要内容提示： 投资者可于 2023 年 06 月 05 日(星期一) 至 06 月 09 日(星期五)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 aladdindmb@163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海阿拉丁生化科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布公司 2022 年年度报告及 2023 年第一季度报告，为便于广大投资者更 全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计 划于 2023 年 06 月 12 日 上午 09:00-10:00 举行 2022 年度暨 2023 年第一季度 业绩说明会，就投资者关心的问题进行交流。 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2023-020 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何 ...

2023 年第一季度报告 证券代码：688179 证券简称：阿拉丁 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年 | | | --- | --- | --- | --- | | | | 同期增减变动幅 | | | | | 度(%) | | | 营业收入 | | 86,543,299.85 | -5.93% | | 归属于上市公司股东的净利润 | | 17,251,791.95 | -44.38% | ...

Financial Performance - The company's operating revenue for 2022 was CNY 378,104,008.92, representing a year-on-year increase of 31.44% compared to CNY 287,661,274.91 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 92,331,491.84, a slight increase of 3.32% from CNY 89,360,811.30 in 2021[20]. - The net cash flow from operating activities decreased significantly by 388.41%, resulting in a net outflow of CNY 43,261,325.55, compared to a positive cash flow of CNY 15,000,074.03 in 2021[20][22]. - The total assets at the end of 2022 reached CNY 1,476,476,729.30, marking a substantial increase of 58.40% from CNY 932,104,036.16 at the end of 2021[20]. - The basic earnings per share for 2022 was CNY 0.65, down 26.97% from CNY 0.89 in 2021[21]. - The total net assets attributable to shareholders increased by 13.56% to CNY 974,721,715.97 at the end of 2022, compared to CNY 858,317,915.63 at the end of 2021[20]. - The company's comprehensive gross profit margin for 2022 was 58.65%, indicating a strong profitability position despite potential future competition[71]. - The company's inventory turnover rate was 0.56 times, which is below the industry average, indicating slower inventory movement and potential financial risks[72]. Research and Development - Research and development expenses accounted for 10.30% of operating revenue in 2022, an increase of 2.42 percentage points from 7.88% in 2021[21]. - The company applied for 5 new patents during the reporting period, including 3 invention patents and 2 utility model patents[31]. - Total R&D investment reached approximately ¥38.93 million, a 71.79% increase compared to the previous year, accounting for 10.30% of operating income[49]. - The number of R&D personnel increased to 171, up from 119 in the previous year, indicating a growth rate of approximately 43.7%[54]. - The company has developed over 3,200 analytical methods, enhancing its quality control capabilities and product performance characterization[57]. - The company is committed to enhancing its R&D capabilities and optimizing product structure to maintain and improve its industry position[117]. Corporate Governance - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and senior management to ensure orderly management[121]. - The company has not reported any significant changes in its independence or ability to operate autonomously from its controlling shareholders[121]. - The company has established specialized committees, including audit, nomination, remuneration, and strategic committees, to enhance governance[151]. - The company has maintained transparency in information disclosure, ensuring timely and accurate communication with investors[184]. - The company has received a standard unqualified opinion in its internal control audit report for the year 2022[181]. Market Position and Strategy - The company operates in four main fields: high-end chemistry, life sciences, analytical chromatography, and materials science[32]. - The company is one of the most comprehensive manufacturers of research reagents in China, focusing on import substitution and brand development[41]. - The market for high-end reagents in China remains significantly underserved, indicating potential growth opportunities for the company[38]. - The company has established a fully-owned subsidiary, Aladdin Technology Pte. Ltd., to explore overseas market expansion[113]. - The company plans to expand its product line in four key areas: high-end chemicals, life sciences, analytical chromatography, and materials science[117]. Environmental Compliance - The company has complied with all environmental regulations, with no penalties received during the reporting period[183]. - The company has implemented a comprehensive environmental monitoring plan, ensuring compliance with industry standards for wastewater, waste gas, and noise detection[193]. - The company has established a dedicated hazardous waste warehouse and ensures compliance with hazardous waste disposal regulations through qualified third-party services[198]. - The company reported a total of 5.933 tons of waste from scrapped pharmaceuticals generated during the year, with no remaining inventory at year-end[188]. Employee Welfare and Compensation - The company actively promotes employee welfare, including social insurance and health check-ups, to retain talent[160]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.3769 million RMB[143]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 2.1525 million RMB[143]. - The company has established a performance evaluation mechanism for senior management, linking compensation to the achievement of operational and profitability goals[178]. Future Outlook - The company provided guidance for 2023, projecting revenue growth of 10% to 1.32 billion, driven by new product launches and market expansion[134]. - The company plans to implement cost-cutting measures aimed at improving operating margins by 5%[136]. - The company is exploring partnerships with tech firms to leverage AI technologies, aiming to integrate these into its product suite by 2024[134].